ArticleCancer science2013

Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.

Yong Sang Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.